# Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer

> **NCT02716961** · NA · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 208 (estimated)

## Conditions studied

- Bladder Cancer
- Gemcitabine and Cisplatin Chemotherapy
- Epirubicin Instillation
- Recurrence
- Prognosis

## Interventions

- **DRUG:** Gemcitabine, cisplatin

## Key facts

- **NCT ID:** NCT02716961
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2016-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02716961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02716961, "Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02716961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*